CDEK
← All drugs Report issue

vaniprevir

Small moleculeexperimental

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep. — Wikipedia

Clinical trial activity

12 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
8
Phase 3
3
Phase 4
0

Earliest trial started Jul 1, 2007 (NCT00518622)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc1cccc3c1CN(C3)C(=O)O2)C(=O)NS(=O)(=O)C1CC1
Mol. weight
757.95 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • mk7009
  • mk7009
  • mk7009
  • mk 7009
  • mk-7009
  • mk-7009
  • mk-7009
  • mk-7009
  • vanihep
  • vaniprevir
  • vaniprevir
  • vaniprevir
  • vaniprevir
  • vaniprevir
  • vaniprevir
  • vaniprevir
  • vaniprevir

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01678131Phase 1Oct 1, 2012Merck
NCT01405560Phase 3Sep 1, 2011Merck
NCT01405937Phase 3Aug 1, 2011Merck
NCT01370642Phase 3Jun 1, 2011Merck
NCT00895882Phase 2Nov 1, 2010Merck
NCT00954993Phase 1Jan 1, 2010Merck
NCT00943761Phase 2Oct 1, 2009Merck
NCT01010906Phase 1Jul 1, 2009Merck
NCT00880763Phase 2Apr 1, 2009Merck
NCT00704405Phase 2Mar 1, 2009Merck
NCT00704184Phase 2Jul 1, 2008Merck
NCT00518622Phase 1Jul 1, 2007Merck
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit121232007
1 organizations
Page 1 / 1